SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-16-755383
Filing Date
2016-11-01
Accepted
2016-11-01 16:26:25
Documents
55
Period of Report
2016-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q d271640d10q.htm 10-Q 562406
2 EX-31.1 d271640dex311.htm EX-31.1 5937
3 EX-31.2 d271640dex312.htm EX-31.2 5933
4 EX-32.1 d271640dex321.htm EX-32.1 3826
11 GRAPHIC g271640g72x53.jpg GRAPHIC 122859
  Complete submission text file 0001193125-16-755383.txt   2859878

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT ntla-20160930.xml EX-101.INS 365173
6 XBRL TAXONOMY EXTENSION SCHEMA ntla-20160930.xsd EX-101.SCH 35868
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ntla-20160930_cal.xml EX-101.CAL 44800
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ntla-20160930_def.xml EX-101.DEF 101896
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20160930_lab.xml EX-101.LAB 292952
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20160930_pre.xml EX-101.PRE 202433
Mailing Address 130 BROOKLINE STREET SUITE 201 CAMBRIDGE MA 02139
Business Address 130 BROOKLINE STREET SUITE 201 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37766 | Film No.: 161965085
SIC: 2835 In Vitro & In Vivo Diagnostic Substances